"folic acid" from_date:2012

Supplementation with (6S)-5-methyltetrahydrofolic acid appears as effective as folic acid in maintaining maternal folate status while reducing unmetabolised folic acid in maternal plasma: a randomised trial of pregnant women in Canada. Folic acid supplementation is recommended during pregnancy to support healthy fetal development; (6)-5-methyltetrahydrofolic acid ((6)-5-MTHF) is available in some commercial prenatal vitamins as an alternative to folic acid, but its effect on blood folate status during pregnancy is unknown. To address this, we randomised sixty pregnant individuals at 8-21 weeks' gestation to 0·6 mg/d folic acid or (6)-5-MTHF × 16 weeks. Fasting blood specimens were collected at baseline and after 16 weeks (endline). Erythrocyte and serum folate were quantified via

Dietary food folate and synthetic folic acid co-exposure patterns with elevated depressive symptoms: Findings from NHANES 2005-2018. This study investigates the associations of dietary food folate and synthetic folic acid co-exposure patterns with elevated depressive symptoms, a relationship previously underexplored. A total of 25,354 participants who participated in the National Health of folate, as follows: "folate deficiency group" to cluster 1, "dietary folate sufficiency group" to cluster 2, "folic acid supplement group" to cluster 3, and "mixed sources folic acid group" to cluster 4. Compared with cluster 1, participants in cluster 2 had lower risks of elevated depressive symptoms (OR = 0.78[0.68, 0.89]), and participants in cluster 3 and cluster 4 did not. Cross-sectional data

Folic acid and plasma lipids: Interactions and effect of folate supplementation. Dyslipidaemia and hyperhomocysteinemia are known risk factors for cardiovascular disease. While it is evident that optimization of plasma lipid is associated with low risk of cardiovascular disease in the general population, it is not yet fully clear whether reduction of homocysteinemia is associated data, pathophysiological observations and meta-analyses of randomized clinical trials suggest that folic acid supplementation may modestly but significantly improve plasma lipid levels, lipid atherogenicity, and atherosclerosis-related early vascular damage, and that folic acid supplementation may significantly reduce the risk of cerebrovascular disease. Considering the low-cost and high safety

Folic Acid-Fortified Iodized Salt and Serum Folate Levels in Reproductive-Aged Women of Rural India: A Nonrandomized Controlled Trial. India has a disproportionately high prevalence of neural tube defects, including spina bifida and anencephaly (SBA), causing a high number of stillbirths, elective pregnancy terminations, and child mortality; India contributes a large proportion of the global burden of SBA. Thirty years after folic acid was shown to be effective in reducing SBA prevalence, only about one-quarter of such births are prevented globally through cereal grain fortification. To determine the association of folic acid-fortified iodized salt with serum folate concentrations among nonpregnant and nonlactating women of reproductive age. This nonrandomized controlled trial using

Serum Concentrations of Folate Forms Following Supplementation of Multimicronutrients with 400 µg or 800 µg Mix of (6S)-5-Methyltetrahydrofolate and Folic Acid (1:1) in Women of Childbearing Age. A mixture of (6S)-5-methyltetrahydrofolate-calcium salt ((6S)-5-MTHF-Ca) and folic acid (FA) from multimicronutrient supplements may show a dose-dependent effect on serum folate concentrations . The study compares fasting concentrations of serum folate spices after 8 weeks of either 400 or 800 µg day of 1:1 folate mixture in 172 nonpregnant women. Serum (6S)-5-MTHF concentrations raise from a mean (SD) of 19.1 (13.4) to 73.9 (19.6) nmol L in the 800 µg group and from 17.5 (9.4) to 54.5 (21.1) nmol L in the 400 µg group (p < 0.001 within-group changes). The raise in serum (6S)-5-MTHF is stronger

Intake and biomarkers of folate and folic acid as determinants of chemotherapy-induced toxicities in patients with colorectal cancer: a cohort study. Capecitabine is an oral chemotherapeutic drug showing antitumor activity through inhibition of thymidylate synthase, an enzyme involved in folate metabolism. There are concerns about high intake of certain vitamins, and specifically folate, during chemotherapy with capecitabine. Whether folate or folic acid, the synthetic variant of the vitamin, impact treatment toxicity remains unclear. We studied associations between intake and biomarkers of folate as well as folic acid and toxicities in patients with colorectal cancer (CRC) receiving capecitabine. Within the prospective COLON (Colorectal cancer: Longitudinal, Observational study on Nutritional

Low dose daily folic acid (400 μg) supplementation does not affect regulation of folate transporters found present throughout the terminal ileum and colon of humans: a randomized clinical trial. Folic acid supplementation during the periconceptional period reduces risk of neural tube defects in infants, but concern over chronic folic acid exposure remains. An improved understanding of folate absorption may clarify potential risks. Folate transporters have been characterized in the small intestine, but less so in the colon of healthy, free-living humans. The impact of folic acid fortification or supplementation on regulation of these transporters along the intestinal tract is unknown. The objective was to characterize expression of folate transporters/receptor (FT/R) and folate hydrolase

Correlation of Folic Acid Metabolic Gene Polymorphisms, Homocysteine, Vitamin B12, and Red Blood Cell Folate with Adverse Pregnancy Outcomes. This study aims to investigate the relationship between folic acid (FA) metabolic gene polymorphisms, homocysteine (Hcy), vitamin B12 (Vit B12), and red blood cell folate (RBCF) with adverse pregnancy. The findings of this study can help in the prevention

Associations of folate/folic acid supplementation alone and in combination with other B vitamins on dementia risk and brain structure: evidence from 466,224 UK Biobank participants. Previous researchers have tried to explore the association between folate/folic acid intake and dementia incidence, but the results remain controversial. We evaluated the associations of folate/folic acid supplementation alone and in combination with other B vitamins on dementia risk and brain structure. A total of 466,224 UK Biobank participants were investigated. Cox proportional hazards models were used to assess the associations between folate/folic acid supplementation status and the risk of Alzheimer's disease (AD) and vascular dementia (VD). Multivariable linear regression models were employed to evaluate

Impact of high-dose folic acid supplementation in pregnancy on biomarkers of folate status and 1-carbon metabolism: An ancillary study of the Folic Acid Clinical Trial (FACT). Periconceptional folic acid (FA) supplementation is recommended to prevent the occurrence of neural tube defects. Currently, most over-the-counter FA supplements in Canada and the United States contain 1 mg FA and some women are prescribed 5 mg FA/d. High-dose FA is hypothesized to impair 1-carbon metabolism. We aimed to determine folate and 1-carbon metabolism biomarkers in pregnant women exposed to 1 mg or 5 mg FA. This was an ancillary study within the Folic Acid Clinical Trial (FACT), a randomized, double-blinded, placebo-controlled, phase III trial designed to assess the efficacy of high-dose FA to prevent

Associations between folic acid supplement use and folate status biomarkers in the first and third trimesters of pregnancy in the mirec pregnancy cohort study. Achieving optimal folate status during early gestation reduces risk of neural tube defects (NTD). While inadequate folate intake remains a concern, it is becoming increasingly common for individuals to consume higher than recommended doses of folic acid (FA) with minimal additional benefit. Here, we sought to investigate the determinants, including FA supplement dose and use, of plasma total and individual folate vitamer concentrations in the first and third trimester of pregnancy. Using data from the Maternal-Infant Research on Environmental Chemicals (MIREC) Study, a cohort exposed to mandatory FA fortification, we measured

falciparum (Global Partnership to Roll Back Malaria 2001). However, despite these recommendations, SP continues to be advised for intermittent preventive treatment in pregnancy (IPTp) and intermittent preventive treatment in infants (IPTi), whether the person has malaria or not (WHO 2013). Description of the intervention Folate (vitamin B9) includes both naturally occurring folates and folic acid concentrations compared to children without malaria infection, but plasma folate levels were similar (Bradley-Moore 1985). Why it is important to do this review The malaria parasite needs folate for survival and growth in humans. For individuals, adequate folate levels are critical for health and well-being, and for the prevention of anaemia and neural tube defects. Many countries rely on folic acid

Cost-effectiveness of folic acid fortification of flours in prevention of neural tube defects: a scope of the secondary literature Gwasanaeth Tystiolaeth Evidence Service Adroddiad cwmpasu Scoping report 1 Cost-effectiveness of folic acid fortification of flours in prevention of neural tube defects: a scope of the secondary literature Compiled by Claire Morgan, Senior Evidence and Knowledge which directly addresses the question .................................................. 4 Cost-effectiveness of mandatory flour fortification....................................... 4 Folic acid dosage ..................................................................................................... 5 Cost composition

. Preventive Medication Folic acid is the synthetic form of folate, a water-soluble B vitamin. Folic acid is usually given as a multivitamin, prenatal vitamin, or single supplement, and is also used to fortify cereal grain products. Folate occurs naturally in foods such as dark green leafy vegetables, legumes, and oranges. However, most women do not receive the recommended daily intake of folate annual prevalence of anencephaly and spina bifida combined was 6.5 cases per 10,000 live births.1-3 Daily folic acid supplementation in the periconceptional period can prevent neural tube defects.1,2Folic acid is the synthetic form of folate, a water-soluble B vitamin (B9). Folic acid is usually given as a multivitamin, prenatal vitamin, or single supplement. It is also used to fortify cereal grain

A community-based randomized controlled trial providing weekly iron-folic acid supplementation increased serum- ferritin, -folate and hemoglobin concentration of adolescent girls in southern Ethiopia. Adequate micronutrient status during adolescence can break the inter-generational cycle of malnutrition. This study evaluated the effect of community-based weekly iron-folic acid supplementation (WIFAS) on serum ferritin (SF), serum folate (SFol) and hemoglobin concentration (Hb) among adolescent girls. A community-based, individually randomized-controlled trial (RCT) was conducted in four villages of Wolaita and Hadiya zones. Adolescent girls (n = 226) aged 10-19 years were recruited and randomly assigned (n = 113/group) into: (i) WIFAS and (ii) control (no intervention) groups. Anthropometry

Gestational Folate and Folic Acid Intake among Women in Canada at Higher Risk of Pre-Eclampsia. Periconceptional folic acid (FA) supplementation is recommended to prevent neural tube defects; however, the extent to which recommendations are met through dietary sources and supplements is not clear. Our objective was to evaluate the dietary and supplemental intakes of FA in a Canadian pregnancy cohort and to determine the proportions of pregnant women exceeding the Estimated Average Requirement (EAR) and Tolerable Upper Intake Level (UL). FACT (the Folic Acid Clinical Trial) was an international multicenter, randomized, double-blinded, placebo-controlled, phase III trial investigating FA for the prevention of pre-eclampsia in high-risk pregnancies. Participants were enrolled from Canadian

levels. Concomitant use is possible with careful management of the interaction. Contents 1. Benefits of using the combination 2. Managing folate deficiency Prevention of neural tube defects 3. Risks of using the combination 4. Managing the interaction 5. Measure baseline phenytoin levels Repeat phenytoin levels Managing dose adjustments 6. Stopping folic acid 7. Counselling 8. Women of child-bearing potential 9. Further information 10. Bibliography Benefits of using the combinationIt may be necessary for people to take both phenytoin and folic acid. Folic acid may be required: * to treat folate deficiency * for women who are pregnant or planning pregnancy to reduce the risk of congenital abnormalities Long-term treatment with phenytoin can reduce folate levels. Folate deficiency in a patient taking

studiesLicence and supplyInformation for patientsBibliographyRationale for using folic acid supplementsBetween 7 and 30% of people discontinue methotrexate in the first year due to adverse effects.  The incidence of adverse events is associated with reduced adherence to methotrexate. Some of the adverse effects of methotrexate are likely to be due to folate antagonism.The common adverse effects associated regimensDoseFolic acid 5mg weekly, on a different day to the methotrexate dose, is the most commonly recommended regimen from clinical studies and national guidance.The dose should be high enough to prevent folate deficiency.  The dose can be increased to 10mg if the person experiences any adverse effects to the methotrexate.No evidence was identified to support increasing the dose beyond 10mg.Use of folic acid

(20%) of 472 children had vitamin B deficiency (≤203 pg/mL), 16 (3%) of 475 children had serum folate deficiency (<4 ng/mL), and 44 (9%) of 468 children had zinc deficiency (<66 μg/dL). 611 children in the iron-folic acid plus micronutrients group and 626 children in the iron-folic acid alone group had a blood sample collected at the end of the 90-day supplementation period and were included Comparative effectiveness of daily therapeutic supplementation with multiple micronutrients and iron-folic acid versus iron-folic acid alone in children with mild-to-moderate anaemia in rural India: an open-label, randomised controlled trial. Anaemia is a major public health problem among children younger than 5 years and supplementation with iron-folic acid alone has not been found to result

Flour Fortification with Folic Acid Flour Fortification with Folic Acid | Royal College of Nursing We use cookies to ensure you receive the best experience on our website. By continuing to use our website, you agree to the use of cookies and similar technologies.Read our cookie policy and how to disable them I agree Search Menu submit * Membership * Employment and Pay * Professional with Folic Acid You are here: Royal College of Nursing / Professional Development / Publications / Flour Fortification with Folic Acid Published: 22/03/2020 Publication code: 009 111 * Summary * Order a hard copy * Copyright Please select Summary Order a hard copy Copyright Evidence suggests that fortifying flour with folic acid can help to support the prevention of neural tube defects